{
    "nctId": "NCT01292408",
    "briefTitle": "Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients",
    "officialTitle": "Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients:a Pilot Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "hypoxia markers",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with core-biopsy proven invasive adenocarcinoma of the breast\n* Any tumor with a size \u2265 1cm (NOT inflammatory breast cancer)\n* WHO-performance score 0 or 1\n* Written informed consent\n\nExclusion Criteria:\n\n* Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol\n* Hampered liver or kidney function\n* Serious gastro-intestinal disease\n* Neurological disease (including epilepsy)\n* Hematological disease\n* Psoriasis\n* Porphyry\n* G6PD deficiency\n* Hypersensitivity for quinine\n* Use of gold containing drugs, oxyphenbutazone, phenylbutazon, digoxin\n* Operation for breast cancer foreseen within 14 days after inclusion in the study.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}